← Human Trials & Peer-Reviewed Studies
The combined effect of Parathyroid hormone (1-34) and whole-body Vibration exercise in the treatment of postmenopausal OSteoporosis (PaVOS study): a randomized controlled trial
Plain-language guide to PMID 31309239 (2019): randomized controlled trial study of Teriparatide and Parathyroid Hormone (PTH 1-84).
Key Facts
- PMID
- 31309239
- Journal
- Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
- Year
- 2019
- Study type
- Randomized Controlled Trial
- Authors
- Jepsen DB et al. (6 authors)
- DOI
- 10.1007/s00198-019-05029-z
What This Study Did, in Plain Language
What Was Tested
Researchers studied Teriparatide and Parathyroid Hormone (PTH 1-84) in this randomized controlled trial publication.
Treatment effects of combining teriparatide and whole-body vibration exercise (WBV) vs teriparatide alone in twelve months were compared using bone mineral density (BMD), bone microarchitecture, and bone turnover markers.
Whole-body vibration exercise (WBV) has been found to stimulate muscle and bone strength in some studies.
Who Took Part
The age groups tagged for this paper are middle-aged adults, older adults and people over 80, women only.
Bone mineral density (BMD) and bone microarchitecture, bone turnover markers, and sclerostin measurements were obtained.
Data were analyzed using a linear mixed regression model with adjustment for baseline values or robust cluster regression in an intention-to-treat (ITT) analysis.
How the Study Was Run
The design is described as randomized.
The participants were allocated by chance, so the Teriparatide group and the comparison group should start out alike.
WBV consisted of three sessions a week (12 min, including 1:1 ratio of exercise:rest).
What Was Measured
Topics PubMed links to this paper include Absorptiometry, Photon, Biomarkers, Bone Density, Bone Density Conservation Agents, Bone Remodeling, Combined Modality Therapy and Exercise Therapy.
The authors tagged it with the keywords postmenopausal osteoporosis, randomized controlled trial, teriparatide and whole-body vibration.
What This Means in Plain Language
The paper is a randomized study of Teriparatide and Parathyroid Hormone (PTH 1-84).
Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2019 (Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA), a journal based in England.
More context: the Teriparatide compound page and the Parathyroid Hormone (PTH 1-84) compound page, all human trials.
Our Notes on the Compounds
Teriparatide: A parathyroid hormone fragment, PTH(1-34), with human trials and approved-pen labeling; the research vial is not the approved pen.
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.